A detailed history of Prem Watsa (Fairfax Financial Holdings LTD) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Fairfax Financial Holdings LTD holds 21,158 shares of RVNC stock, worth $54,376. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,158
Holding current value
$54,376
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
N/A
21,158 New
21,158 $54,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track Prem Watsa's Portfolio

Track Prem Watsa Portfolio

Follow Prem Watsa (Fairfax Financial Holdings LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairfax Financial Holdings LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fairfax Financial Holdings LTD and Prem Watsa with notifications on news.